Septerna, Inc.
SEPN
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.7B
Close$
$-30.86
181.8% downside
Current Fair Value
181.8% downsideOvervalued by 181.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.70 Billion |
|---|---|
| Enterprise Value | $1.72 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.1 |
| Beta | 2.29 |
| Outstanding Shares | 45,040,075 |
Return
| Return on Equity | -6.27% |
|---|---|
| Return on Assets | -4.28% |
| Return on Invested Capital | -10.52% |
Valuation & Multiples
| P/E Ratio | -69.83 |
|---|---|
| PEG | 146.94 |
| Price to Sales | 18.86 |
| Price to Book Ratio | 4.71 |
| Enterprise Value to Revenue | 17.38 |
| Enterprise Value to EBIT | -33.51 |
| Enterprise Value to Net Income | -71 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.27 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.43
Average shareholder expectationRevenue Estimate
$19.22 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.41
Average shareholder expectationRevenue Estimate
$20.78 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3782▲ 37.82% |
|---|---|
| Total Calls | 1,041,000▲ 1326.03% |
| Total Puts | 393,752▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 105.31%▲ 3.16% |
|---|---|
| Total Invested | $1.59B▲ 44.56% |
| Investors Holding | 166▲ 41.00% |
ESG Score
No data
About Septerna, Inc.
75 employees
CEO: Dr. Jeffrey T. Finer M.D., Ph.D. Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic disea...